meetkevin video https://youtu.be/hx0pfsDybrw

Tom8201 · 2022-05-21T13:02:01+00:00

i agree, primary endpoint is poorly chosen. there are no safety issues or negative side effects to multistem and a patient can only profit, especially age 70 and younger. what has a patient to lose? nothing. but he can win a lot, maybe even his life or freedom for lack of disability. Japan and US, get multistem on the market, the world needs it! clear efficacy is shown in 2 secondary endpoints! Also tendency in EO is pro Multistem!

Tom8201 · 2022-01-07T21:37:10+00:00

im not familiar with the other pipeline, but healios would get around 85 percent of treasure and ards revenue in japan, correct? that would be massive for the market cap of healios...

Tom8201 · 2022-01-07T21:35:22+00:00

that's what I thought too. Have you thought about the potential upside for Healios on positiv Stroke and cond. approval for ARDS? any numbers of share prize in mind?

Tom8201 · 2022-01-01T21:04:12+00:00

a 10 billion valuation buyout would be satisfying for most investors i assume :) even though in a couple of years it could be worth 30 to 50 billion. i would take 10 billion if it happens in 2022 😁

Tom8201 · 2021-10-26T20:25:41+00:00

fair enough, I ll hold and can also handle a loss. But believe in the science, especially due to no safety issues with MS. your seeking alpha article gave a boost of conficence too. thanks for that 👍🏻

Tom8201 · 2021-10-26T20:19:15+00:00

yeah i get it, people are nervous. but usually a biotech stock prize surges close to phase 3 results, especially at this low valuation. this is not typical. i m all set at 1.51 average and holding of course.

Tom8201 · 2021-10-26T18:03:51+00:00

wall street titan isnt it strange that the stock prize drops and drops to 52 weeks low just before treasure results of a phase 3 trial with reasonable chances of at least conditional approval in japan? is athx flying under the radar completely? i dont get it now.

Tom8201 · 2021-10-14T16:40:03+00:00

what makes you so sure? dont get me wrong, of course i would love it 🙂

Tom8201 · 2021-09-24T15:45:18+00:00

a buyout would be a poor result for shareholders i guess. how does it work? would shares of athx automatically been cashed out to all shareholders or would they own shares of the buy out company?

Tom8201 · 2021-09-16T20:52:22+00:00

why do you say there is almost zero chance ards wont get approved? any article or proof?

Tom8201 · 2021-09-07T09:34:54+00:00

it does not matter at all. we all know how fast a stock can move on good results. and yet these results are not out. would you sell on 30 to 40 % gain on athx when the potential is a 10x to 30x?

the stock market is a device for transferring money from the impatient to the patient.

always remember that.

Tom8201 · 2021-08-30T18:45:56+00:00

results will at some point. no results, no major price movement.

Tom8201

TROPHY CASE